Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
0.4378
+0.0178 (4.24%)
Mar 31, 2025, 3:33 PM EDT - Market open
Company Description
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues.
Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer.
It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema.
Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.
Abpro Holdings, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Jin Suk |
Contact Details
Address: 68 Cummings Park Drive Woburn, Massachusetts 01801 United States | |
| Phone | 800 396 5890 |
| Website | abpro.com |
Stock Details
| Ticker Symbol | ABP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893219 |
| Employer ID | 87-1013956 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jin Wook Suk | Chief Executive Officer and Chairman of the Board |
| Eugene Y. Chan M.D. | Co-Founder |
| Dr. Robert J. Markelewicz Jr., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 8-K | Current Report |
| Mar 24, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 7, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 12, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | 424B3 | Prospectus |
| Feb 7, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 3, 2025 | UPLOAD | Filing |